Connect with us

Published

on

Jeff Bezos pops champagne after emerging from the New Shepard capsule after his spaceflight on July 20, 2021.
Blue Origin

All things must die, according to the poet Alfred Lord Tennyson, but that could be about to change.

A growing number of tech billionaires have decided they want to use their enormous wealth to try to help humans “cheat death.”

Amazon‘s Jeff Bezos, Alphabet‘s Larry Page, Oracle‘s Larry Ellison and Palantir’s Peter Thiel are just a few of the super-rich who have taken a keen interest in the fast-emerging field of longevity, according to interviews, books and media reports.

While breakthroughs are far from guaranteed, they hope that various medicines, therapies and other life science technologies will enable humans to live well beyond 100 years old and possibly to 200, 300, or even longer.

But are their efforts going to benefit humanity as a whole or just an elite few? It’s a tricky question that divides opinion.

The filter down effect

“Technologies that initially are only affordable to the rich typically become more widely available with time,” Stefan Schubert, a researcher at the London School of Economics and Political Science who specializes in “effective altruism,” told CNBC. Indeed, this is true of everything from air travel to smartphones and medicine.

Tech investor Jaan Tallinn, the co-founder of Skype, told CNBC that Silicon Valley’s quest to live forever will eventually benefit humanity as a whole.

“I think involuntary death is clearly morally bad, which makes the quest for longevity a morally noble thing to engage in,” Tallinn said. “Early adopters always tend to pay more and take larger risks than the ‘mass market,’ so if therapies start off on the expensive/risky side, that’s to be expected.”

Tallinn added that he thinks it’s “counterproductive” to require that a new service be available to everyone before anyone is allowed to use it, but he said he understands the instinct.

Sean O hEigeartaigh, co-director of Cambridge University’s Center for the Study of Existential Risk, told CNBC that many advances in longevity science could have broad benefits, adding that they could reduce the occurrence or severity of older age-related diseases including dementia and heart health.

“Extending max lifespan significantly in the near-term seems unlikely to me; but identifying and arresting aging-related factors that increase preponderance and severity of age-related conditions is more plausible,” Ó hÉigeartaigh said.

Some are concerned that the Earth’s finite resources could come under strain if people live longer, healthier lives.

However, by the time meaningful life extension advances are made, Ó hÉigeartaigh expects population numbers to be more stable in more parts of the world.

“I expect meaningful lifespan extension to be a century or more away, and by then I expect a parallel change in societal attitude towards euthanasia,” he said, adding that he thinks euthanasia will be more acceptable and more common in the coming years.

What about climate change?

While some believe that billionaires should be able to spend their money on what they see fit, not everyone thinks tech billionaires should be using their money to fund life extension research.

Jon Crowcroft, a computer science professor at Cambridge University, told CNBC they’d be better off pumping more of their billions into climate change mitigation technologies instead of longevity research.

“It’s a bit pointless living forever on a dying planet,” said Crowcroft.

But Tallinn told CNBC he finds the tech billionaire’s efforts to support longevity research “commendable.”

“I think it’s generally unfair to pit good causes against each other in a world where most resources are wasted on morally unimportant or even reprehensible things,” Tallinn said.

Billionaire’s chasing immortality

Bezos, the second richest man in the world behind Elon Musk, has invested some of his $199 billion into a new “rejuvenation” start-up called Altos Labs, according to a report from MIT Technology Review earlier this month.

The anti-ageing start-up, which is said to be pursuing biological reprogramming technology, is reportedly also backed by Russian-Israeli venture capitalist Yuri Milner, who made a fortune as an early investor in Facebook.

Elsewhere, Oracle founder Ellison has donated more than $370 million to research about aging and age-related diseases, according to The New Yorker.

Meanwhile, Google founders Sergey Brin and Larry Page helped launch Calico, a secretive venture that’s tracking mice from birth to death in the hope of finding markers for diseases like diabetes and Alzheimer’s, according to a report in The New Yorker. Calico is part of Alphabet, the holding company that also owns Google.

One of the biggest advocates for life extension among the tech billionaires is Thiel, who co-founded PayPal and Palantir and backed Donald Trump’s 2016 presidential campaign.

Peter Thiel, co-founder of PayPal Inc.
VCG | Getty Images

In 2006, he donated $3.5 million to support anti-ageing research through the non-profit Methuselah Mouse Prize foundation. “Rapid advances in biological science foretell of a treasure trove of discoveries this century, including dramatically improved health and longevity for all,” he said at the time. Thiel had upped his investment in Methuselah Mouse Prize foundation to $7 million by 2017, according to Time.

According to The New Yorker, Thiel and Bezos have both invested in San Francisco-based Unity Biotechnology, a company whose founder reportedly said he wants to “vaporize a third of human diseases in the developed world.”

Life extension stocks?

On the other side of the Atlantic, British billionaire Jim Mellon told CNBC last September that he was planning to take Juvenescence, his own life extension company, public in the next six to 12 months.

It’s yet to happen, but Juvenescence is continuing to invest in a wide range of anti-ageing therapies that it thinks have the potential to extend the human life.

One of those investments is Insilico Medicine, which aims to use artificial intelligence for drug discovery. Juvenescence has also backed AgeX Therapeutics, a California-headquartered firm trying to create stem cells that can regenerate ageing tissue, and LyGenesis, which wants to develop a technology that uses lymph nodes as bioreactors to regrow replacement organs.

Other billionaires, including Mike Cannon-Brookes, the co-founder of Australian software firm Atlassian, and NEX Group founder Michael Spencer, have invested in Juvenescence.

Continue Reading

Technology

Astronomer HR chief Kristin Cabot resigns following Coldplay ‘kiss cam’ incident

Published

on

By

Astronomer HR chief Kristin Cabot resigns following Coldplay 'kiss cam' incident

Chris Martin of Coldplay performs live at San Siro Stadium, Milan, Italy, in July 2017.

Mairo Cinquetti | NurPhoto | Getty Images

Days after Astronomer CEO Andy Byron resigned from the tech startup, the HR exec who was with him at the infamous Coldplay concert has left as well.

“Kristin Cabot is no longer with Astronomer, she has resigned,” a company spokesperson wrote in an email to CNBC Thursday. Cabot was the company’s chief people officer.

Cabot and Byron, who is married with children, were shown in an intimate moment on the ‘kiss cam’ at a recent Coldplay show in Boston, and immediately hid when they saw their faces on the big screen. Lead singer Chris Martin said, “Either they’re having an affair or they’re just very shy.” An attendee’s video of the incident went viral.

Byron resigned from the company on Saturday. Both Cabot and Byron have been removed the company’s leadership team webpage.

Pete DeJoy, Astronomer’s interim CEO, wrote in a post earlier this week that recent and unexpected national attention has turned the company into “a household name.”

In May, the New York-based company, which commercializes open source software, announced a $93 million investment round led by Bain Ventures and other investors, including Salesforce Ventures.

Continue Reading

Technology

Musk’s Starlink hit with outage day after rollout of T-Mobile satellite service

Published

on

By

Musk's Starlink hit with outage day after rollout of T-Mobile satellite service

Jakub Porzycki | Nurphoto | Getty Images

Elon Musk‘s satellite internet service Starlink said it had a “network outage” on Thursday. The company said it was working on a solution.

There were more than 60,000 reports of an outage on Downdetector, a site that logs issues.

Starlink is owned and operated by SpaceX, which is also run by Musk.

Musk apologized for the outage on his social media platform X and said, “Service will be restored shortly.”

Musk posted earlier Thursday that the company’s direct-to-cell-phone service was “growing fast” following the announcement that T-Mobile‘s Starlink-powered satellite service was available to the public.

T-Mobile said the T-Satellite service was built to keep phones connected “in places no carrier towers can reach.”

Starlink didn’t immediately respond to a request for comment.

Starlink internet speeds and reliability decrease with popularity, a recent study found.

It wasn’t immediately clear if the T-Satellite service was affected by or involved in the outage.

Read more CNBC tech news

CNBC’s Lora Kolodny contributed to this story.

Continue Reading

Technology

Intel beats on revenue, slashes foundry investments as CEO says ‘no more blank checks’

Published

on

By

Intel beats on revenue, slashes foundry investments as CEO says 'no more blank checks'

The Intel logo is displayed on a sign in front of Intel headquarters on July 16, 2025 in Santa Clara, California.

Justin Sullivan | Getty Images

Intel reported second-quarter results on Thursday that beat Wall Street expectations on revenue, as the company’s new CEO Lip-Bu Tan announced significant cuts in chip factory construction. The stock ticked higher in extended trading.

Here’s how the chipmaker did versus LSEG consensus estimates:

  • Earnings per share: Loss of 10 cents per share, adjusted.
  • Revenue: $12.86 billion versus $11.92 billion estimated

Intel said it expects revenue for the third-quarter of $13.1 billion at the midpoint of its range, versus the average analyst estimate of $12.65 billion. The chipmaker said that it expects to break even on earnings while analysts were looking for earnings of 4 cents per share.

For the second quarter, Intel reported a net loss of $2.9 billion, or 67 cents per share, compared with a $1.61 billion net loss, or 38 cents per share, in the year-earlier period. Earnings per share were not comparable to analyst estimates due to an $800 million impairment charge, “related to excess tools with no identified re-use,” the company said. That resulted in an EPS adjustment of about 20 cents.

The report was Intel’s second since Lip-Bu Tan took over as CEO in March, promising to make the chipmaker’s products competitive again, and to reduce bureaucracy and layers of management, including slashing staff in Oregon and California.

In a memo to employees published on Thursday, Tan said that the first few months of his tenure had “not been easy.” He said that the company had “completed the majority” of its planned layoffs, amounting to 15% of the workforce, and that it plans to end the year with 75,000 employees. Intel previously said it was trying to reduce operating expenses by $17 billion in 2025.

Intel shares are up about 13% this year as of Thursday’s close after plummeting 60% in 2024, their worst year on record.

Tan also announced several other spending cuts in the memo, particularly in the company’s costly foundry division, which makes chips for other companies and is still looking for a big customer to anchor the business.

Intel said its foundry business had an operating loss of $3.17 billion on $4.4 billion in revenue.

Tan said that Intel had cancelled planned fab projects in Germany and Poland, and will consolidate its testing and assembly operations in Vietnam and Malaysia. He added that the company would slow down the pace of its construction of a cutting-edge chip factory in Ohio, depending on market demand and if it can secure big customers for the facility.

“Over the past several years, the company invested too much, too soon – without adequate demand,” Tan wrote. “In the process, our factory footprint became needlessly fragmented and underutilized.”

Tan wrote that the company’s forthcoming chip manufacturing process, called 14A, will be built out based on confirmed customer commitments.

“There are no more blank checks. Every investment must make economic sense,” Tan wrote.

The company’s client computing group, which is primarily comprised of sales of central processors for PCs, had $7.9 billion in sales, down 3% on an annual basis.

Revenue in the data center group, which includes some AI chips but is mostly central processors for servers, rose 4% to $3.9 billion. Tan wrote in his memo that Intel wants to regain market share in data center chips, and is looking for a permanent leader for the business. Longtime rival Advanced Micro Devices has increasingly been winning server business from cloud customers.

Tan added he would personally review and approve all chip designs before they are taped out, which is the final step of the design process before a new chip is manufactured.

WATCH: How U.S. companies are mitigating Trump tariffs with foreign trade zones

How U.S. companies are mitigating Trump tariffs with foreign trade zones

Continue Reading

Trending